| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41591-018-0204-6 |
| P698 | PubMed publication ID | 30374197 |
| P50 | author | Petra Reinke | Q62091040 |
| Hans-Dieter Volk | Q84015469 | ||
| Leila Amini | Q85651000 | ||
| Dimitrios L Wagner | Q88139149 | ||
| Lisa-Marie Burkhardt | Q92657041 | ||
| P2093 | author name string | Levent Akyüz | |
| Desiree J Wendering | |||
| Michael Schmueck-Henneresse | |||
| P2860 | cites work | Genome engineering using the CRISPR-Cas9 system | Q22122027 |
| RNA-guided human genome engineering via Cas9 | Q24598394 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 | ||
| Therapeutic genome editing: prospects and challenges | Q28087380 | ||
| Progress and prospects: immune responses to viral vectors | Q28264531 | ||
| Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis | Q28290053 | ||
| NCBI BLAST: a better web interface | Q29614461 | ||
| The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 | Q29619324 | ||
| CTLA-4 control over Foxp3+ regulatory T cell function | Q29619413 | ||
| Strategies to modulate immune responses: a new frontier for gene therapy | Q33713999 | ||
| The global burden of group A streptococcal diseases | Q33991045 | ||
| Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage | Q34046684 | ||
| The human immune response to streptococcal extracellular antigens: clinical, diagnostic, and potential pathogenetic implications | Q34092321 | ||
| Deep sequencing of the human TCRγ and TCRβ repertoires suggests that TCRβ rearranges after αβ and γδ T cell commitment | Q34263653 | ||
| Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease | Q34491035 | ||
| High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. | Q34507554 | ||
| Regulatory T cells and immune tolerance in the intestine | Q34789108 | ||
| Peripheral education of the immune system by colonic commensal microbiota. | Q35341308 | ||
| Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities | Q35850673 | ||
| Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct manners | Q36018275 | ||
| Diversity and evolution of class 2 CRISPR-Cas systems | Q36256836 | ||
| TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40 | Q37197918 | ||
| Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells | Q37414711 | ||
| A multifunctional AAV-CRISPR-Cas9 and its host response | Q37731772 | ||
| How to use antistreptolysin O titre. | Q38183799 | ||
| IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs | Q38521750 | ||
| Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants. | Q38662974 | ||
| Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans | Q39257312 | ||
| Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency | Q41008417 | ||
| Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. | Q43733156 | ||
| Virus treatment questioned after gene therapy death | Q45746742 | ||
| Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes | Q45771097 | ||
| Immunity to CRISPR Cas9 and Cas12a therapeutics | Q45873745 | ||
| HCMV-specific T-cell therapy: do not forget supply of help. | Q45990164 | ||
| DNA methylation controls Foxp3 gene expression | Q46391168 | ||
| A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg. | Q52886049 | ||
| Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. | Q52936537 | ||
| “Dirty little secrets”—Endotoxin contamination of recombinant proteins | Q61883733 | ||
| Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population | Q90727473 | ||
| A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells | Q90788612 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Streptococcus pyogenes | Q131271 |
| Cas9 | Q16965677 | ||
| P304 | page(s) | 242-248 | |
| P577 | publication date | 2018-10-29 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population | |
| P478 | volume | 25 |
| Q60912963 | A Self-Deleting AAV-CRISPR System for Genome Editing |
| Q89446452 | A Small Molecule-Controlled Cas9 Repressible System |
| Q92876148 | AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer |
| Q94458455 | AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9 |
| Q64089162 | Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research |
| Q91943206 | Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases |
| Q101559243 | Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1 |
| Q93376356 | Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy |
| Q91866605 | Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy |
| Q100737258 | Base editing: advances and therapeutic opportunities |
| Q99589832 | CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients |
| Q90593405 | CRISPR-Edited Immune Effectors: The End of the Beginning |
| Q92692728 | Correction of the aprt Gene Using Repair-Polypurine Reverse Hoogsteen Hairpins in Mammalian Cells |
| Q92017672 | Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse |
| Q91828960 | Delivering Cas9/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient 'hit-and-run' genome editing |
| Q64236104 | Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing |
| Q99724691 | Delivery Approaches for Therapeutic Genome Editing and Challenges |
| Q64386928 | Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing |
| Q104134953 | Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases |
| Q63740288 | Disruptive Technology: CRISPR/Cas-Based Tools and Approaches |
| Q64237389 | Gene Delivery in Lipid Research and Therapies |
| Q90618258 | Gene editing and CRISPR in the clinic: current and future perspectives |
| Q91901314 | Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9 |
| Q91259898 | Identification of preexisting adaptive immunity to Cas9 proteins in humans |
| Q92093599 | Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy |
| Q95309871 | Immunity to Cas9 as an Obstacle to Persistent Genome Editing |
| Q90564966 | Immunogenicity of Cas9 Protein |
| Q104617773 | Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1 |
| Q91707988 | Mechanisms of Immune Tolerance in Liver Transplantation-Crosstalk Between Alloreactive T Cells and Liver Cells With Therapeutic Prospects |
| Q100455120 | Modulating gene regulation to treat genetic disorders |
| Q64097789 | Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes |
| Q89652462 | Novel Engineered Programmable Systems for ADAR-Mediated RNA Editing |
| Q91904925 | Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs |
| Q89518736 | RNA-targeting CRISPR systems from metagenomic discovery to transcriptomic engineering |
| Q64039611 | Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases |
| Q92415298 | Sharpening the Molecular Scissors: Advances in Gene-Editing Technology |
| Q92979222 | Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy |
| Q98465703 | Specificity of the T Cell Response to Protein Biopharmaceuticals |
| Q61796711 | Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9 |
| Q96816785 | The delivery challenge: fulfilling the promise of therapeutic genome editing |
| Q92419599 | The next generation of CRISPR-Cas technologies and applications |
| Q89686956 | The promise and challenge of therapeutic genome editing |
| Q104111445 | Tools for experimental and computational analyses of off-target editing by programmable nucleases |
| Q91536696 | Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety |
| Q90576004 | Weakly immunogenic CRISPR therapies |
Search more.